Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05980169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 23, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv8
  2. Primary completion date: Dec 1, 2025 to Jun 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v7
  3. Eligibility criteria expanded, about 45 words
    • Study description expanded, about 1 word
    v6
  4. Re-verified, no change to tracked fieldsv5
  5. Primary completion date: Dec 1, 2024 to Dec 1, 2025v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date changed from estimate of Dec 1, 2023 to Nov 29, 2023
    • Eligibility criteria expanded, about 39 words
    • Secondary endpoints: 7 to 8
    • Site details revised
  2. Start date: Aug 1, 2023 to Dec 1, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to assess the efficacy of SensoniQ® Treatment Station in preventing or reducing chemotherapy induced peripheral neuropathy symptoms (CIPNS) in patients receiving frontline carboplatin and paclitaxel chemotherapy for a gynecologic malignancy. This study will also assess the improvement of CIPNS in patients who have previously received carboplatin and paclitaxel therapy with persistent Grade 2 or worse neuropathy. The main questions this clinical trial aims to answer are: 1. To investigate the efficacy of SensoniQ® Treatment Station on the prevention or reduction of CIPNS in gynecologic oncology patients receiving front line carboplatin and paclitaxel. 2. To investigate the efficacy of SensoniQ® Treatment Station on the improvement of existing CIPNS in patients who previously received chemotherapy with platinum agent and paclitaxel for a gynecologic malignancy
Trial Details
NCT Number NCT05980169
Lead Sponsor Augusta University
Conditions
(from sponsor)		 Gynecologic Cancer, Neuropathy;Peripheral
Related terms Neuritis
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov